November 28, 2007
Stratatech Awarded $975,000 NIH Grant
Stratatech Corporation has received a $975,000 Fast-Track SBIR Grant from the National Institute on Aging. Under this Grant, Stratatech will continue its work to develop a new manufacturing process and related technology for use in the production of its skin tissue products. Stratatech will work to incorporate new manufacturing techniques to enable closed, aseptic processing and continuous process monitoring of Stratatech’s engineered skin tissue products. These products are being developed for the treatment of burns, trauma, and chronic wounds. In the United States alone, millions of people annually suffer from chronic ulcers, and that number is growing as the population ages. Diabetic, venous stasis and pressure ulcers are particularly problematic for aged individuals and impact an elderly patient's quality of life, often resulting in serious complications such as pain, infection, and the devastating consequence of amputation.
Stratatech, which currently has 25 employees, was established in 2000 and currently operates within the MGE Innovation Center in University Research Park in Madison, WI. Its flagship product, StrataGraft™ skin tissue, is currently being evaluated in a clinical trial for the treatment of burns and other severe skin trauma. Stratatech is also developing a portfolio of engineered skin tissue products that are genetically modified to promote the healing of chronic wounds, such as diabetic ulcers, venous stasis ulcers and pressure ulcers (bedsores). Stratatech’s products are based on a patented, unique source of pathogen-free human skin cells that was identified at the University of Wisconsin.